La somatostatina inibisce la crescita di sarcoma di Kaposi in topi nudi mediante l'inibizione della neoangiogenesi.

Translated title of the contribution: Somatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis

A. Corsaro, S. Thellung, V. Villa, S. Arena, D. Noonan, A. Albini, G. Schettini, T. Florio

Research output: Contribution to journalArticlepeer-review


Somatostatin and its analogs are active in the inhibition of the proliteration of sst receptor positive endocrine neoplasms, however their activity and mechanism in non-endocrine tumors is not clear. Somatostatin effectively inhibited the growth of a Kaposi's sarcoma xenograft in nude mice, yet in vitro the tumor cells did not express any known somatostatin receptors and were not growth inhibited by somatostatin. Histological examination revealed limited vascularization in the somatostatin treated tumors as compared to the controls. Somatostatin was a potent inhibitor of angiogenesis in an in vivo assay. In vitro, somatostatin inhibited endothelial cell growth and invasion. Migration of monocytes, important mediators of the angiogenic cascade, was also inhibited by somatostatin. Both cells types expressed somatostatin receptor mRNAs. These data demonstrate that somatostatin is a potent anti-tumor angiogenesis compound directly affecting both endothelial and monocytic cells. The debated function of somatostatin in tumor treatment and the design of therapeutic protocols should be reexamined considering these data.

Translated title of the contributionSomatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis
Original languageItalian
Pages (from-to)273-276
Number of pages4
JournalMinerva Endocrinologica
Issue number4
Publication statusPublished - 2001


Dive into the research topics of 'Somatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis'. Together they form a unique fingerprint.

Cite this